The partners will utilize their IP, expertise, and know-how to offer the first system enabling ultra-high resolution bioprinting of microstructures such as vascular networks or capillaries. The technology is an important complement to CELLINK's extrusion based bioprinting platform, enabling combined prints from the two printing technologies for anatomically relevant results.
Prellis Biologics has developed a proprietary ultra-fast, multi-photon laser-based bioprinting technology. Live-cell imaging methods inspired the creation of a tissue printing system designed to replicate real human tissue structures, at never-before seen resolutions. Resolutions that match the microvascular structures of human tissues and extracellular matrix have yet to be seen with any other bioprinting technology. CELLINK as the commercialization partner is responsible for design of the system, user interface development, and sales of the system, ink and consumables to researchers and end-users in the pharmaceutical and academic field.
"We believe in the democratization of science. It's not only our team who will lead discovery and therapeutics development using true-to-life 3D structures, but scientists across the globe. Putting this technology into the hands of dedicated researchers is the fastest path to bring scientific advancements to the field and solutions to real people," said Melanie Matheu, CEO, Prellis Biologics.
The first bioprinting system offered by the two parties will be the CELLINK Holograph-X Bioprinter - Powered by Prellis Biologics and will have a retail price of approximately $1.2 million. The system will enable the first-ever bioprinting of pre-vascularized tissue structures demonstrated to support tissue growth 10x larger than standard spheroid cultures. Most importantly, the system works with any CAD file developed by researchers to match their own goals for organ and organoid tissue culture. The Holograph-X Bioprinter will allow for in-lab manufacturing of capillary containing organ structures and tissues for transplantation, therapeutics screening, and complex 3D culture development. The first system will be commercially available early 2019.
"We are excited to announce this partnership where we combine key strengths of our two companies resulting in cutting edge technology to our partners and customers empowering them to advance their research in the field of 3D-bioprinting of human organs," said Erik Gatenholm, CEO, CELLINK.
This partnership will further CELLINK's product portfolio in the 3D-bioprinting field offering a complete platform for highly advanced researchers in the field.
CELLINK has created one of the world's first universal Bioinks, today used by many of the world's most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK's universal Bioink shows excellent results and can be used in both CELLINK's proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. CELLINK AB is listed at Nasdaq First North with the ticker CLNK. Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company's Certified Adviser.
About Prellis Biologics
Prellis Biologics, Inc. developed the first holographic printing system able to match and accurately replicate human organ and tissue structures for R&D and organ transplantation. The combined resolution and speed of Prellis Biologics' printing technology allows for full human organ systems to be created with cell-compatible biomatrices. We are dedicated to solving the global human organ transplant shortage. Prellis Biologics, Inc. was founded in 2016 and is a privately held company based in San Francisco, CA.